410
Participants
Start Date
January 31, 2021
Primary Completion Date
January 31, 2028
Study Completion Date
January 31, 2028
Primary debulking surgery
Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
Neoadjuvant chemotherapy
3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
PARPi
For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
Zhongshan Hospital Fudan University, Shanghai
Obstetrics & Gynecology Hospital of Fundan University, Shanghai
Shanghai First Maternity and Infant Hospital, Shanghai
Shanghai Jiao Tong University School of Medicine Xinhua Hospital, Shanghai
Obstetrics & Gynecology Hospital of Fudan University
OTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Shanghai First Maternity and Infant Hospital
OTHER
Shanghai Gynecologic Oncology Group
OTHER_GOV